Each year, 40,000 new, China's first brain tumor registration research platform line.

(Health Times reporter Yao Xine) Recently, China's first national brain tumor registration research platform (NBTRC) officially launched, the platform of the National Center for Clinical Medicine of Neurological Diseases lasted 3 years to organize the establishment of the country's 43 neurosurgery technical advantage units to participate in the construction.
the establishment of the national brain tumor registration research platform will gradually include the Capital Medical University affiliated Beijing Tiantan Hospital, Peking University First Hospital, Capital Medical University Sanbo Brain Hospital and other 23 provinces, municipalities and autonomous regions of the country 43 different levels of hospital clinical data, the future will be China's first brain tumor professional clinical research public service platform, based on brain tumor "big data" large-scale, multi-center, high-quality diagnosis and treatment outcome research and clinical norms.At the establishment ceremony of the
platform, Hu Jianping, deputy director of the Statistical Information Center of the State Health and Planning Commission, Zhang Zhaofeng, director of the Biomedicine Division of the Social Development Department of the Ministry of Science and Technology, Yu Jing, director of the Medical Quality Division of the Medical Administration of the State Health and Planning Commission, Pan Suyan, deputy director of the Beijing Municipal Hospital Administration, and Pan Junhua, director of the Science and Education Department of the Beijing Municipal Hospital Administration, will give policy guidance and deliver a speech.
as chairman of the scientific committee of the platform, academician Zhan Qimin and academician Hejie personally attended the meeting to support. At the same time, Zhou Liangfu, Zhao Jizong, Academician Qiang Boqin, Professor Wang Congjun, Executive Vice President of Beijing Tiantan Hospital, Director of Brain Surgery at Prince of Wales Hospital in Hong Kong, Professor Ji Jiafu, Dean of The Oncology Hospital of Peking University, Professor Yuxin Yan, Dean of the School of Basic Medicine, Peking University, attended the meeting together as Vice Chairman of the Scientific Committee to witness the platform line. Also serving as Vice Chairman of the Scientific Committee are the Director of the Department of Medicine of Zhejiang University, academician Duan Shumin, a neuroscience expert, and academician Ofsu Shuwu, a pathological expert.
in addition, after the early recruitment, research and formal lying on the platform 43 core units and network members responsible for leadership, brain tumor professional discipline leaders are to participate in the release activities, and participated in the subsequent multi-center collaborative network training session and quality control briefing.
breaking the data "island" to achieve the overall management of brain tumor cases
it is understood that registration as a clear tumor epidemiology, understanding the status of treatment and observe clinical efficacy of research means have been carried out a lot abroad.
in order to effectively integrate resources, build a unified application platform for data, relying on the Capital Medical University affiliated Beijing Tiantan Hospital in the field of neurosurgery and neurology excellent scientific and technological influence, the National Center for Clinical Medicine of Neurological Diseases as the first national clinical medical research center approved, since its establishment in 2013, the national brain tumor registration research platform (NBTRC) as one of the first support of the key projects. This is the first attempt based on the multi-center registration and collaborative research of brain tumor, which has great academic value and social significance.
Optimization Management Model Platform units can realize data benefit sharing
platform release site, including Beijing Tiantan Hospital affiliated with Capital Medical University, Beijing University First Hospital, Capital Medical University Sanbo Brain Hospital and other 43 different levels of hospitals from 23 provinces, municipalities and autonomous regions of the country signed on-site. It is understood that in order to effectively integrate resources, the platform has been built to cover 43 member units, the annual volume of surgery more than 40,000 cases of collaborative network.
at present, the platform has realized the Beijing Tiantan Hospital and Sanbo Brain Hospital based on the pre-machine system of structured diagnosis and treatment data interconnection, nearly 30,000 diagnostic data efficiently pooled in the data platform, good trial run. With the gradual improvement of the platform function, the remaining 41 member units will be connected to the data in different ways, and enjoy the right to call relevant data and conduct clinical research.
each year to add 40,000 brain tumor case data Intelligent module highlights the "big data" advantages
more than 2 years, through the close cooperation of clinicians, methodology experts and IT engineers, for the brain tumor clinical diagnosis and treatment, patient follow-up and other constraints, has systematically developed a more complete, intelligent functional modules, including structured clinical diagnosis and treatment data, standardized image data, intelligent follow-up system, big data display and benefit sharing mechanism platform management.
estimates, with the advantage of China's population advantage, the platform can increase the total pathological spectrum of brain tumor synopsis each year more than 40,000 cases. These well-structured, geographically representative brain tumor big data, the future will become the end of the event of one of the world's largest brain tumor queue, can carry out large-scale, multi-center, high-quality diagnosis and treatment outcome research based on the real world and clinical diagnosis and treatment norms research, medical quality homogenization evaluation research, new technology and new products forward-looking comparative evaluation research, but also to carry out basic and clinical close integration of translational medical research. The platform is expected to become a win-win platform for cooperation in the field of brain tumor in China, a leading platform for research on clinical behavior and a platform for new technology verification and transformation.
.